Wolfgang Miesbach on VTE and Cancer: A 20-Year Signal That Can’t Be Ignored
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn:
”VTE and Cancer: A 20-Year Signal That Can’t Be Ignored.
In a nationwide Danish cohort of 138,049 first‑ever VTE patients (DVT 51.7%, PE 39.3%, SVT 8.9%), followed from 1996–2022, Søren Martiny et al. demonstrate a clear two‑phase cancer risk pattern after thrombosis.
Median age at VTE was 66 years, 52% were women, and 43.8% of events were provoked (≈48% by major factors such as recent surgery or fracture/trauma, the remainder by minor factors including pregnancy, HRT, hormonal contraception, or recent hospitalization).
At the time of the thrombotic event itself, all patients were cancer‑free (prior cancers other than non‑melanoma skin cancer were excluded), so any subsequent malignancy reflects incident cancer emerging after the index VTE rather than known active cancer at baseline.
Year One: The Occult Cancer Signal
During the first year after VTE, the absolute cancer risk was 4.0% and the standardized incidence ratio (SIR) versus the general population was 3.45 (95% CI 3.36–3.55), capturing both unprovoked and provoked events and holding across DVT, PE, and SVT.
The authors previously showed that this early excess is largely driven by cancers presenting within months of VTE, consistent with the concept of VTE as a harbinger of occult malignancy.
Years 2–20: The Persistent Cancer Risk
Beyond year one, cancer risk declines but remains 9–16% higher than expected for up to 20 years (SIR 1.09–1.16 across follow‑up windows), regardless of age group, sex, VTE type (SVT, DVT, or PE), primary vs secondary diagnosis, comorbidity burden, or whether the index event was provoked or unprovoked. After 20 years, the SIR approximates 1.00, suggesting the excess risk is time‑limited but clinically meaningful over two decades.
This long‑term signal is driven particularly by cancers linked to smoking, obesity, and alcohol—lung, pharynx, larynx, esophagus, stomach, liver, pancreas, colon—as well as haematologic malignancies, supporting the idea that VTE and cancer share upstream lifestyle and genetic determinants rather than a simple “occult cancer at baseline” explanation.”
Read the full article here.
Article: Venous Thromboembolism and 20-Year Cancer Risk: A Danish Population-Based Cohort Study
Authors: Søren K. Martiny, Vincent Lanting, Dóra K. Farkas, Nick van Es, Henrik T. Sørensen
Stay updated on all scientific advances with Hemostasis Today.
-
Feb 23, 2026, 18:13Fight4Hematology Supports Research and Empowers the Next Generation – ASH
-
Feb 23, 2026, 17:59Wolfgang Miesbach: Real-World Evidence of Emicizumab on Joint Outcomes in Hemophilia A
-
Feb 23, 2026, 17:56Shiny K Kajal: The Transfusion Reaction We Often Miss
-
Feb 23, 2026, 17:53Radheshyam Meher: Contributing to the Transfusion Evidence Round-Up for International Childhood Cancer Day 2026
-
Feb 23, 2026, 17:46Mahesan Subramaniam: The Physiological Impact of Anger on Immunity
-
Feb 23, 2026, 17:42Bryan Fry: First Evidence That Bothrops atrox Venom Directly Activates Human Factor VII
-
Feb 23, 2026, 17:34Bastu Odoka: Why Blood Should NOT be Left at the Bedside to ‘Warm’
-
Feb 23, 2026, 17:28Henry Burkitt: Patients Are Challenging How the Medicines Policy System Works in England
-
Feb 23, 2026, 16:50Mutaz Al‑Sabah: Interesting Webinar on FH in Women is Now Available to Watch